Detalhe da pesquisa
1.
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
J Immunother
; 32(6): 655-66, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19483644